JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 18, 2006; DOI: 10.1124/jpet.106.112268

This Article
Right arrow Full Text (PDF)
Right arrow Data supplement
Right arrow All Versions of this Article:
jpet.106.112268v1
320/1/266    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koukouritaki, S. B.
Right arrow Articles by Hines, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koukouritaki, S. B.
Right arrow Articles by Hines, R. N.


Received for publication August 14, 2006.
Revised October 12, 2006.
Accepted for publication October 17, 2006.

Identification and functional analysis of common human flavin-containing monooxygenase 3 (FMO3) genetic variants

Sevasti B. Koukouritaki 1, Mark T. Poch 1, Marilyn C. Henderson 2, Lisbeth K. Siddens 2, Sharon K. Krueger 2, Jonathan E. VanDyke 2, David E. Williams 2, Nicholas M. Pajewski 1, Tao Wang 1, Ronald N. Hines 1*

1 Medical College of Wisconsin 2 Oregon State University

* Address correspondence to: E-mail: rhines{at}mcw.edu

Abstract

Flavin-containing monooxygenases (FMOs) are important for the disposition of many therapeutics, environmental toxicants, and nutrients. FMO3, the major adult hepatic FMO enzyme, exhibits significant interindividual variation. Eighteen FMO3 single nucleotide polymorphism (SNP) frequencies were determined in 202 Hispanics (Mexican descent), 201 African Americans, and 200 non-Latino whites. Using expressed recombinant enzyme with methimazole, trimethylamine, sulindac, and ethylenethiourea, the novel structural variants, FMO3 E24D and K416N, were shown to cause a modest changes in catalytic efficiency, while a third novel variant, FMO3 N61K, was essentially devoid of activity. The latter variant was present at an allelic frequency of 5.2% in non-Latino whites and 3.5% in African Americans, but was absent in Hispanics. Inferring haplotypes using PHASE V2.1, the greatest haplotype diversity was observed in African Americans followed by non-Latino whites and Hispanics. Haplotype 2A and 2B, consisting of a hypermorphic promoter SNP cluster (-2650C>G, -2543T>A, and -2177G>C) in linkage with synonymous structural variants was inferred at a frequency of 27% in the Hispanic population, but only 5% in non-Latino whites and African Americans. This same promoter SNP cluster in linkage with one or more hypomorphic structural variant also was inferred in multiple haplotypes at a total frequency of 5.6% in the African American study group, but less than 1% in the other two groups. The sum frequencies of the hypomorphic haplotypes H3[15,167G>A (E158K)], H5B [-2650C>G, 15,167G>A (E158K), 21,375C>T (N285N), 21,443A>G (E308G)], and H6 [15,167G>A (E158K), 21,375C>T (N285N)] were 28% in Hispanics, 23% in non-Latino whites and 24% in African Americans.


Key words: FMO3, flavin-containing monooxygenase, genetic variation, haplotype analysis, human, kinetic analysis




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.